Payers

Physicians have been facing increasing workloads making it difficult to practice medicine as they were trained, but an accountable care organization might provide an opportunity for real change to deliver high-value, compassionate care.

COVID-19 hospital visits by adolescents nearly doubled; government to release list of drugs Medicare will be able to negotiate prices for; Rite Aid gears up for bankruptcy while facing lawsuits over alleged opioid involvement.

The Biden administration is expected to unveil the first 10 drugs identified for drug price negotiations Tuesday; American nursing homes are disappearing; gender-affirming surgeries tripled in the United States between 2016-2019.

In 2023, the United States was in the midst of the largest drug shortage in a decade, including lifesaving platinum-based medications to treat a variety of cancers.

The revisions to the ACO REACH model are expected to add predictability and stability while advancing health equity.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

The program, which scales an accountable care organization (ACO) model across all major payers in Vermont, reduced Medicare spending and hospitalizations while improving patient care.

Patients were twice as likely to get a colorectal cancer screening and 50% more likely to get a breast cancer screening in their first year of Medicare coverage.

Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease.

There is a right way and a wrong way to inform a patient about a switch from the reference product to a biosimilar, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.

Coverage of ASCO sessions and posters that addressed lessons from the Oncology Care Model and concerns about the Enhancing Oncology Model, which launched shortly after the annual meeting ended.

Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.

Presentation of the COMMANDS trial offered practice-changing results for luspatercept.

Physicians and health care groups have lined up to support the Value in Health Care Act, which could create new incentives to adopt value-based care.

The playbook from the 3 organizations highlights 5 best practices for data sharing from organizations with real-world experience in value-based care arrangements.

Despite having 8 adalimumab biosimilars on the market now, patients may only see 1 or 2 available through their insurance, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.

A new analysis finds branded insulin glargine (Lantus) still has a majority of total market volume and new drug starts despite competition from Semglee, an interchangeable biosimilar.

An online survey identified that documentation requirements and communication issues with health plans are associated with providers modifying clinical decisions to avoid medication prior authorization.

Medication formulary policies represent a key determinant of access to medication and can be leveraged to advance pharmacoequity and health equity writ large.

After the Supreme Court ruled reimbursement cuts to 340B hospitals were done unlawfully, CMS is proposing to repay hospitals and providers in the program with a lump sum that has repercussions for other hospitals because of the agency’s need to be budget neutral.

Two abstracts presented at the 2023 American Society of Clinical Oncology annual meeting evaluated biosimilar adoption across oncology practices and highlighted the role payers play in preventing or promoting adoption.

After 7 years, competition for Humira is here. The first adalimumab biosimilar launched in January, but an additional 8, including an interchangeable product, will hit the US market in July.

The Act4Biosimilars Action Plan seeks to increase biosimilar adoption by at least 30 percentage points in 30-plus countries by 2030.